How to buy BioCryst Pharmaceuticals stock (BCRX)

BioCryst Pharmaceuticals is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.67 – an increase of 4.92% over the previous week. BioCryst Pharmaceuticals employs 536 staff and has a trailing 12-month revenue of around $412.6 million.

Our top picks for where to buy BioCryst Pharmaceuticals stock

Buy BioCryst Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

BioCryst Pharmaceuticals stock price (NASDAQ: BCRX)

Use our graph to track the performance of BCRX stocks over time.

BioCryst Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$7.67
52-week range	$4.03 - $8.88
50-day moving average more info button	$7.61
200-day moving average more info button	$6.73
Wall St. target price	$14.82
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.61

Is it a good time to buy BioCryst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCryst Pharmaceuticals price performance over time

Historical closes compared with the close of $7.67 from 2024-12-24

1 week (2024-12-19)	3.79%
1 month (2024-11-26)	2.40%
3 months (2024-09-26)	1.19%
6 months (2024-06-25)	26.15%

1 year (2023-12-26)	26.15%
2 years (2022-12-22)	-31.46%
3 years (2021-12-22)	13.84
5 years (2019-12-26)	141.96%

BioCryst Pharmaceuticals financials

Revenue TTM	$412.6 million
Operating margin TTM	6.57%
Gross profit TTM	$10.9 million
Return on assets TTM	-4.25%
Return on equity TTM	-1925.37%
Profit margin	-30.01%
Book value	$-2.26
Market Capitalization more info button	$1.5 billion

TTM: trailing 12 months

BioCryst Pharmaceuticals share dividends

We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.

BioCryst Pharmaceuticals share price volatility

Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $4.03 up to $8.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 1.887. This would suggest that BioCryst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals, Inc. , a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd. ; Seqirus UK Limited; Shionogi & Co.

Frequently asked questions

null
What percentage of BioCryst Pharmaceuticals is owned by insiders or institutions?
Currently 1.145% of BioCryst Pharmaceuticals shares are held by insiders and 85.944% by institutions. How many people work for BioCryst Pharmaceuticals?
Latest data suggests 536 work at BioCryst Pharmaceuticals. When does the fiscal year end for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals's fiscal year ends in December. Where is BioCryst Pharmaceuticals based?
BioCryst Pharmaceuticals's address is: 4505 Emperor Boulevard, Durham, NC, United States, 27703 What is BioCryst Pharmaceuticals's ISIN number?
BioCryst Pharmaceuticals's international securities identification number is: US09058V1035 What is BioCryst Pharmaceuticals's CUSIP number?
BioCryst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 09058V103